Oral Antiviral Market Size Predicted to Hit USD 43.39 billion by 2031 at 2.1% CAGR, Says AMR

According to the report published by Allied Market Research, the global oral antiviral market generated USD 35.21 billion in 2021, and is estimated to reach USD 43.39 billion by 2031, witnessing a CAGR of 2.1% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.

Impact of Covid-19 on Oral Antiviral Market:

• The COVID-19 pandemic positively affected the growth of the oral antiviral market, owing to a rise in the number of patients suffering from viral infections. The pandemic led to an increased number of outpatient medical visits, including preventive services, such as screening of patients for various viral diseases, such as HIV, influenza, and other viral infections.
• The pandemic led to a high demand for oral antiviral drugs as people looked for ways to protect themselves from the virus. This led to shortages of some oral antiviral drugs, leading to price hikes and difficulties in accessing the drugs.
• In addition, a rise in regulatory approvals and favorable policies for development of novel therapeutics to treat viral infections is likely to provide lucrative opportunity for the key market players.

What are the Recent Trends in the Oral Antiviral Market?

A rise in the number of product approvals for treating viral infections, increase in awareness about viral infection & treatment options available, a rise in regulatory approvals for treating viral infections, and the growing adoption of strategies by key players are the factors that drive the growth of the global oral antiviral market. Region-wise, the market in North America is likely to dominate from 2022 to 2031.

Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/A12673

Leading players of the global oral antiviral market analyzed in the research include F. Hoffman-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amneal Pharmaceuticals LLC, Viatris Inc., AbbVie Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.

Oral Antiviral Market segmentation can be done based on several factors, including:

The report offers a detailed segmentation of the global oral antiviral market based on indication, drug class, distribution channel, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.

Based on indication, the human immunodeficiency virus (HIV) segment held the largest share in 2021, accounting for more than three-fourths of the global oral antiviral market and would dominate the market in terms of revenue through 2031. The hepatitis segment, on the other hand, is estimated to witness the fastest CAGR of 2.6% during the forecast period. The report also discusses the influenza and others segments.

In terms of drug class, the reverse transcriptase inhibitors segment captured the largest market share of more than half of the global oral antiviral market in 2021 and is expected to dominate the market in terms of revenue through 2031. However, the others segment is likely to achieve the fastest CAGR of 2.4% through 2031.

In terms of distribution channel, the drug store and retail pharmacies segment captured the largest market share of nearly three-fifths of the global oral antiviral market in 2021 and is expected to lead the trail during the forecast period. However, the online providers segment is likely to achieve the fastest CAGR of 3.1% through 2031. The report also studies the protease inhibitors segment.

Based on region, the market in North America was the largest in 2021, accounting for over one-third of the global oral antiviral market in 2021 and is likely to maintain its dominance during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 2.8% from 2022 to 2031. The other regions analyzed in the study include Europe and LAMEA.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/A12673

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

Region Analysis:-

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.